TransactionsValue growth

Consulting M&A’s client Regulis, a UK regulatory affairs advisory business, has been acquired by PharmaLex

By July 15, 2020No Comments

15 July 2020

Kim Wharton, the Founder and Managing Director of Regulis said:“We are delighted with the support we had from CM&A. Their knowledge and expertise in corporate finance within the consulting sector helped us through the challenging moments of the process to achieve an outstanding outcome for staff, clients and shareholders.”

Regulis was founded in 2001 and is now a prominent consultancy company with vast experience of working mainly with companies specialising in pharmaceuticals, biopharmaceuticals, medical devices and cosmetics. Their team of expert pharmaceutical consultants assist in the European and Global arenas and have a strong reputation for obtaining fast, high quality regulatory approvals, as well as providing highly dependable pharmacovigilance, vigilance and GMP / GDP client solutions.

By joining forces with Regulis, PharmaLex will strengthen its already significant footprint in the UK and further increase its market share in this key market.

“The merger with PharmaLex brings significant mutual benefits”, explained Kim Wharton. “Our services in Regulatory Affairs, Pharmacovigilance and Quality Assurance align perfectly within the PharmaLex portfolio. Becoming part of a larger organisation with an excellent reputation and significant global footprint is an exciting step for Regulis”, he added.

“PharmaLex and Regulis joining forces offers tremendous potential to our complementary client bases and will contribute further to the successful development of our significant operations and business in the UK”, explained Jon Jeffery, Head UK / Ireland Region and Managing Director, PharmaLex UK. “Our positive cultures and values are very well-matched and considering the strong organic growth of both businesses over recent years, expanding PharmaLex in the UK with the similarly motivated and well-regarded team at Regulis should bring further, exciting opportunities for all”, added Dr. Thomas Dobmeyer, CEO PharmaLex.

If you wish to discuss in confidence how your business could be of interest to buyers, please get in touch by phoning +44 (0) 7860 442 715 or by emailing